AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca, Bloomberg News reported on Thursday, ...

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...